Good problems to have? Policy and societal implications of a disease-modifying therapy for presymptomatic late-onset Alzheimer’s disease

Life Sciences, Society and Policy

Boris Kantor¹  Ornit Chiba-Falek²  Anna Yang³  Misha Angrist⁴ 

[1]Duke University Department of Neurobiology, 27710-3209, Durham, North Carolina, USA

[2]Duke University Department of Neurology, 311 Research Drive, 27710-2900, Durham, North Carolina, USA

[3]Duke Center For Genomic And Computational Biology, Durham, USA

[4]Duke University, Durham, USA

[5]Initiative for Science and Society and Social Science Research Institute, Duke University, 27708-0222, Durham, North Carolina, USA

关键词: Alzheimer’s;    Therapy;    Access;    Diagnosis;    Gene editing;    Service delivery;    Infrastructure;    Drug pricing;   

DOI  :  10.1186/s40504-020-00106-2

来源: Springer

【 摘 要 】

In the United States alone, the prevalence of AD is expected to more than double from six million people in 2019 to nearly 14 million people in 2050. Meanwhile, the track record for developing treatments for AD has been marked by decades of failure. But recent progress in genetics, neuroscience and gene editing suggest that effective treatments could be on the horizon. The arrival of such treatments would have profound implications for the way we diagnose, triage, study, and allocate resources to Alzheimer’s patients. Because the disease is not rare and because it strikes late in life, the development of therapies that are expensive and efficacious but less than cures, will pose particular challenges to healthcare infrastructure. We have a window of time during which we can begin to anticipate just, equitable and salutary ways to accommodate a disease-modifying therapy Alzheimer’s disease. Here we consider the implications for caregivers, clinicians, researchers, and the US healthcare system of the availability of an expensive, presymptomatic treatment for a common late-onset neurodegenerative disease for which diagnosis can be difficult.

【 授权许可】

CC BY